Genetic basis of inter- And intrastrain differences in diazepam p-hydroxylation in rats

Drug Metabolism and Disposition

Volumn 37, Issue 2, 2009, Pages 268-271

  Sakai, Noriaki ^a   Saito, Konomu ^a   Sakamoto, Kentaro Q ^a   Ishizuka, Mayumi ^a   Fujita, Shoichi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D; CYTOCHROME P450 2D3; DIAZEPAM; HEME; THYMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BROWN NORWAY RAT; CONTROLLED STUDY; CYP2D3 GENE; DARK AGOUTI RAT; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; LIVER MICROSOME; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SEQUENCE ANALYSIS; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; GENE EXPRESSION; HYDROXYLATION; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPECIES SPECIFICITY;

AGOUTI; RATTUS; RATTUS NORVEGICUS;

EID: 59649105834     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024273     Document Type: Article

References (15)

1. Bert B, Fink H, Sohr R, and Rex A (2001) Different effects of diazepam in Fischer rats and two stocks of Wistar rats in tests of anxiety. Pharmacol Biochem Behav 70:411-420.
2. Eichelbaum M and Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 46:377-394.
3. Gonzalez FJ (1988) The molecular biology of cytochrome P450s. Pharmacol Rev 40:243-288.
4. Griebel G, Belzung C, Perrault G, and Sanger DJ (2000) Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology (Berl) 148:164-170.
5. Inaba T, Tait A, Nakano M, Mahon WA, and Kalow W (1988) Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation. Drug Metab Dispos 16:605-608.
6. Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, and Green R (2002) A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam. Psychopharmacology (Berl) 159:188-195.
7. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
8. Saito K, Kim HS, Sakai N, Ishizuka M, Kazusaka A, and Fujita S (2004a) Polymorphism in diazepam metabolism in Wistar rats. J Pharm Sci 93:1271-1278.
9. Saito K, Sakai N, Kim HS, Ishizuka M, Kazusaka A, and Fujita S (2004b) Strain differences in diazepam metabolism at its three metabolic sites in Sprague-Dawley, Brown Norway, Dark Agouti, and Wistar strain rats. Drug Metab Dispos 32:959-965.
10. Sakai N, Saito K, Kim HS, Kazusaka A, Ishizuka M, Funae Y, and Fujita S (2005) Importance of CYP2D3 in polymorphism of diazepam p-hydroxylation. Drug Metab Dispos 33:1657-1660.
11. Serikawa T (2004) Colourful history of Japan's rat resources. Nature 429:15.
12. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
13. Thomas MA, Chen CF, Jensen-Seaman MI, Tonellato PJ, and Twigger SN (2003) Phylogenetics of rat inbred strains. Mamm Genome 14:61-64.
14. van der Laan JW, de Groot G, Wortelboer H, and Noordhoek J (1993) Pharmacokinetic differences of desmethyldiazepam in three outbred Wistar strains related to differences in liver enzyme activities. Pharmacol Toxicol 73:229-232.
15. Yamamoto Y, Tasaki T, Nakamura A, Iwata H, Kazusaka A, Gonzalez FJ, and Fujita S (1998) Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 8:73-82.